Pre-market hot trades in US stocks: MultiSensor AI pre-market down 22.96%; Lixiang Edu pre-market up 19.17%

Tracking Unusual Activity
2025.10.24 08:13
portai
I'm PortAI, I can summarize articles.

MultiSensor AI pre-market down 22.96%; Lixiang Edu pre-market up 19.17%; Wellgistics Health pre-market up 93.65%; Qualigen Therapeutics pre-market up 87.25%; Inhibrx pre-market up 73.20%

Popular Pre-Market Trades in US Stocks

MultiSensor AI, down 22.96% in pre-market trading, has no significant recent news. Trading is active with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

Lixiang Edu, up 19.17% in pre-market trading, has no significant recent news. Trading is active with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

Top Gainers in Pre-Market Trading in US Stocks

Wellgistics Health, up 93.65% in pre-market trading. Based on recent key news:

  1. On October 24, Wellgistics Health's stock price soared 87.89% in after-hours trading, closing at $0.76. This increase was primarily due to the company's launch of HubRx AI, a customized artificial intelligence engine designed for pharmacies, which boosted market confidence in the company's technological innovation.

  2. On October 22, Wellgistics Health announced a partnership with DataVault AI to integrate prescription drug distribution through blockchain technology. This collaboration aims to enhance efficiency and patient outcomes through the PharmaChain digital prescription fulfillment process, driving the stock price up.

  3. On October 22, the company announced that the majority of shareholders approved the replacement of board members Rebecca Shanahan and Michael Peterson, which is seen as a positive adjustment to the company's governance structure, enhancing investor confidence. Technological innovation in the pharmaceutical industry drives stock price volatility.

Qualigen Therapeutics, up 87.25% in pre-market trading, has no significant recent news. Trading is active with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation.

Inhibrx, up 73.20% in pre-market trading. Based on recent key news:

  1. On October 24, Inhibrx Biosciences announced positive top-line results for its registered trial Ozekibart in sarcoma. Ozekibart achieved its primary endpoint in the trial, reducing the risk of disease progression by 52%, and plans to submit a Biologics License Application in the second quarter of 2026. This news significantly boosted the stock price. Source: Reuters

  2. On October 23, Inhibrx announced it would showcase the trial results of Ozekibart in a web broadcast and provide updates on colorectal cancer and synovial sarcoma expansion cohorts. This announcement attracted market attention, further driving the stock price up. Source: Reuters

  3. On October 24, analysts held a positive view on Inhibrx's technical indicators, despite challenging financial performance, with technical indicators showing bullish momentum. This technical signal enhanced market confidence, propelling the stock price up. The biopharmaceutical industry has been active recently, with investors focusing on new drug development progress

Source: Tracking Unusual Activity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer